aortic stenosis
in review
3 min read
Updated 2026-10-19
aortic stenosis
Severe = Vmax ≥4 m/s, mean gradient ≥40 mmHg, AVA ≤1.0 cm². Symptoms or LVEF <50% → valve replacement. Asymptomatic severe AS → exercise test to unmask symptoms; early intervention increasingly offered. TAVI for older patients, SAVR for younger low-risk patients, Heart Team in between. Symptomatic severe AS is preload- and rate-dependent → avoid vasodilators, hypovolaemia and tachycardia.
severity
| Mild | Moderate | Severe | |
|---|---|---|---|
| peak velocity (m/s) | 2.0–2.9 | 3.0–3.9 | ≥4.0 |
| mean gradient (mmHg) | <20 | 20–39 | ≥40 |
| AVA (cm²) | >1.5 | 1.0–1.5 | ≤1.0 |
Small AVA but low gradient — flow is too low to generate a gradient, or the AS is really moderate:
- LVEF <50% → dobutamine stress echo: gradient rises and AVA stays ≤1.0 = true severe; AVA opens up = pseudo-severe (cardiomyopathy)
- LVEF preserved (small hypertrophied LV) → CT aortic valve calcium score (>2000 AU men, >1200 AU women = severe likely)
- confirmed severe low-gradient AS → treat as severe
when to intervene
- symptomatic severe AS — exertional dyspnoea, angina, syncope; untreated survival is poor
- asymptomatic severe AS + LVEF <50%
- severe AS at the time of other cardiac surgery (CABG, aorta) — moderate AS reasonable too (ESC IIa)
- asymptomatic → exercise test where safe; symptoms or BP fall on exercise = symptomatic
- asymptomatic high-risk features → intervention reasonable: very severe AS (Vmax >5 m/s), rapid progression, markedly raised BNP
- asymptomatic severe AS at low procedural risk → early intervention is now an alternative to watchful waiting: EARLY TAVR (2024) cut the composite of death, stroke and CV hospitalisation, driven by a quarter of the surveillance arm needing TAVI within 6 months
TAVI vs SAVR
- older patients → TAVI (transfemoral, suitable anatomy); younger, low surgical risk → SAVR; in between → Heart Team decision on life expectancy vs valve durability
- favour SAVR: bicuspid valve, young age, needs other cardiac surgery (CABG for complex CAD, aortic root), unsuitable anatomy
- favour TAVI: frailty, porcelain aorta, chest radiation or deformity, prior CABG with patent grafts
- TAVI → more new pacemakers and paravalvular leak; SAVR → more bleeding, AKI and new AF
- PARTNER 3 (2019): TAVI at least as good as SAVR in low-risk patients at 1 year
- balloon valvotomy: bridge only (unstable patient, urgent non-cardiac surgery)
After replacement → antithrombotics and valve choice in prosthetic heart valves.
medical management
haemodynamics in severe AS
Fixed outflow obstruction → cardiac output depends on preload and diastolic filling time.
- avoid vasodilators (nitrates, aggressive ACEi/ARB) and over-diuresis in symptomatic severe AS → collapse
- avoid tachycardia — shortens diastole
- hypotension → phenylephrine or norepinephrine; intubation → vasopressor running before induction
- hypertension with asymptomatic AS → treat (adds afterload), titrate carefully
- no drug slows progression (statins don’t)
- HF from severe AS → medical therapy must not delay valve replacement
- follow-up echo: severe asymptomatic at least every 6 months; moderate at least annually; mild (young, no significant calcification) every 2–3 years; sooner if symptoms
key trials
| Trial | Year | N | Comparison | Result |
|---|---|---|---|---|
| PARTNER 3 (2019) | 2019 | 1000 | TAVI vs SAVR, low-risk severe AS | TAVI lower death/stroke/rehospitalisation at 1 y |
| EARLY TAVR (2024) | 2024 | 901 | early TAVI vs surveillance, asymptomatic severe AS | composite ↓ ~50%; no difference in death or stroke |
Prepared 2026-10-19. Not yet verified — check every number against the sources.